These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36115066)

  • 21. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
    Büchner T; Hiddemann W; Wörmann B; Löffler H; Gassmann W; Haferlach T; Fonatsch C; Haase D; Schoch C; Hossfeld D; Lengfelder E; Aul C; Heyll A; Maschmeyer G; Ludwig WD; Sauerland MC; Heinecke A
    Blood; 1999 Jun; 93(12):4116-24. PubMed ID: 10361108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
    Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia.
    Stahl M; Giblin G; Liu Y; Winer ES; Garcia JS; Chen E; Wadleigh M; Ling K; Lindsley RC; Shimony S; Copson K; Charles A; DeAngelo DJ; Stone RM; Nohria A; Luskin MR
    Leuk Res; 2023 Sep; 132():107351. PubMed ID: 37451200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
    Visani G; Lemoli RM; Isidori A; Piccaluga PP; Martinelli G; Malagola M; Gugliotta L; Bonini A; Bonifazi F; Motta MR; Rizzi S; Castellani S; Tura S
    Bone Marrow Transplant; 2001 Apr; 27(8):829-35. PubMed ID: 11477440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.
    Krejci M; Doubek M; Dusek J; Brychtova Y; Racil Z; Navratil M; Tomiska M; Horky O; Pospisilova S; Mayer J
    Ann Hematol; 2013 Oct; 92(10):1397-403. PubMed ID: 23728608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.
    Tsimberidou AM; Stavroyianni N; Viniou N; Papaioannou M; Tiniakou M; Marinakis T; Skandali A; Sakellari I; Yataganas X;
    Cancer; 2003 Apr; 97(7):1721-31. PubMed ID: 12655529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995).
    Cassileth PA; Lee SJ; Litzow MR; Miller KB; Stadtmauer EA; Tallman MS; Lazarus HM; Bennett JM; Paietta E; Dewald GW; Rowe JM;
    Leuk Lymphoma; 2005 Jan; 46(1):55-61. PubMed ID: 15621781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
    Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
    Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.
    Ye P; Pei R; Jin J; Sun J; Li K; Cao J; Zhou D; Lu Y
    Ann Hematol; 2019 Sep; 98(9):2073-2080. PubMed ID: 31201514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
    Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
    Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
    Mandelli F; Vignetti M; Suciu S; Stasi R; Petti MC; Meloni G; Muus P; Marmont F; Marie JP; Labar B; Thomas X; Di Raimondo F; Willemze R; Liso V; Ferrara F; Baila L; Fazi P; Zittoun R; Amadori S; de Witte T
    J Clin Oncol; 2009 Nov; 27(32):5397-403. PubMed ID: 19826132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
    Wang H; Xiao X; Xiao Q; Lu Y; Wu Y
    Medicine (Baltimore); 2020 Jun; 99(24):e20094. PubMed ID: 32541448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the impact of two post-remission therapy regimens on cardiac events in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Hayakawa J; Nakasone H; Minakata D; Fujiwara SI; Gomyo A; Akahoshi Y; Komiya Y; Harada N; Ugai T; Kameda K; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Terasako-Saito K; Kikuchi M; Kimura SI; Kanda J; Kako S; Kanda Y
    Int J Hematol; 2022 Aug; 116(2):239-247. PubMed ID: 35429328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression.
    Al-Kali A; Tibes R; Atherton P; Palmer J; Alkhateeb HB; Patnaik M; Begna K; Gangat N; Hashmi S; He R; Litzow M
    Am J Hematol; 2023 Mar; 98(3):472-480. PubMed ID: 36625066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults.
    Phillips GL; Reece DE; Shepherd JD; Barnett MJ; Brown RA; Frei-Lahr DA; Klingemann HG; Bolwell BJ; Spinelli JJ; Herzig RH
    Blood; 1991 Apr; 77(7):1429-35. PubMed ID: 2009367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
    Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The first results of treatment for adult acute myeloid leukemia according to the AML-01.10 protocol of the Research Group of the Hematology Centers of Russia].
    Parovichnikova EN; Kliasova GA; Sokolov AN; Troitskaia VV; Kokhno AV; Kuz'mina LA; Shaforostova II; Ryzhko VV; Kravchenko SK; Bondarenko SN; Lapin VA; Pristupa AS; Konstantinova TS; Zagoskina TP; Ialykomov IV; Moskov VI; Anchukova LV; Kaporskaia TS; Volodicheva EM; Kaplanov KD; Kondakova EV; Samoĭlova OS; Gavrilova LV; Kulikov SM; Savchenko VG
    Ter Arkh; 2012; 84(7):10-5. PubMed ID: 23038965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.
    Champlin R; Gajewski J; Nimer S; Vollset S; Landaw E; Winston D; Schiller G; Ho W
    J Clin Oncol; 1990 Jul; 8(7):1199-206. PubMed ID: 1694236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.